GATA2 and myeloid neoplasm: In young MCC patients or myeloid neoplasm patients with a history of rare skin cancer, the possibility of primary immunodeficiency must be considered, such as GATA2–deficiency, to allow early detection and the choice of treatment strategies, potentially improving patient outcomes.